Citius Oncology Reports 120% Growth in LYMPHIR Wholesaler Shipments

What happened

Citius Oncology reported preliminary, unaudited sales of 792 LYMPHIR units to U.S. wholesalers in fiscal fourth-quarter 2026, up 120% from the prior quarter, with full fiscal-year results expected in December.

Confirmed

Global impact / market context

Rising wholesaler shipments can signal growing demand for LYMPHIR, a treatment for a type of skin lymphoma. More orders and prescribing institutions could lift product revenue, though wholesaler purchases do not always equal patient use.

Analyst inference

Prescribing centers ordered 950 vials in the quarter versus 926 prior, and 54 institutions had ordered LYMPHIR by October 26, up from 44 on August 14. LYMPHIR launched in the U.S. in December 2025.

Confirmed

What to watch

1. Watch whether Citius meets its stated goal of having LYMPHIR on formulary, which means approved for reimbursement, at 100 priority institutions by year-end. Proposed
2. Track the gap between 950 vials ordered by prescribing centers and 792 units shipped to wholesalers, to see whether inventory is building at distributors or reaching providers. Analyst inference
3. The company expects to report full fiscal-year results in December; investors will compare final audited figures with the preliminary 792-unit wholesaler shipment number. Confirmed

Evidence

• Original source link unavailable